Eli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics. The agreement, centred on the development of RNA ...

SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a ...

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

Eli Lilly (LLY) reported better-than-expected earnings for the second quarter on Thursday. But disappointing results of its much-awaited oral GLP-1 pill sent the stock down 13% in early trading ...

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo© Thomson Reuters ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it may not be as potent as injectable GLP-1 drugs on the market.